Aldeyra Therapeutics (FRA:137) Beginning Cash Position : €131.40 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Aldeyra Therapeutics Beginning Cash Position?

Aldeyra Therapeutics's Beginning Cash Position for the quarter that ended in Mar. 2024 was €131.40 Mil.

Aldeyra Therapeutics's quarterly Beginning Cash Position declined from Sep. 2023 (€142.12 Mil) to Dec. 2023 (€131.44 Mil) and declined from Dec. 2023 (€131.44 Mil) to Mar. 2024 (€131.40 Mil).

Aldeyra Therapeutics's annual Beginning Cash Position increased from Dec. 2021 (€68.91 Mil) to Dec. 2022 (€216.92 Mil) but then declined from Dec. 2022 (€216.92 Mil) to Dec. 2023 (€132.43 Mil).

Aldeyra Therapeutics Beginning Cash Position Historical Data

The historical data trend for Aldeyra Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aldeyra Therapeutics Beginning Cash Position Chart

Aldeyra Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beginning Cash Position

Get a 7-Day Free Trial

42.62

36.52

68.91

216.92

132.43

Aldeyra Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Beginning Cash Position	Get a 7-Day Free Trial															134.89	152.32	142.12	131.44	131.40

Aldeyra Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Aldeyra Therapeutics Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Aldeyra Therapeutics's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Aldeyra Therapeutics (FRA:137) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aldeyra Therapeutics Inc (FRA:137) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

ALDX:USA 137:Germany

Address

131 Hartwell Avenue, Suite 320, Lexington, MA, USA, 02421

Website

https://www.aldeyra.com

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.

Aldeyra Therapeutics (FRA:137) Headlines

No Headlines